Edge Therapeutics treats first patient in Phase III NEWTON II trial of EG-1962 to treat aSAH

US-based, clinical-stage, biotechnology company Edge Therapeutics has treated its first patient in the Phase III Nimodipine microparticles to enhance recovery while reducing toxicity after the subarachnoid hemorrhage (NEWTON II) trial of EG-1962, to …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news